bioTheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic …

SAN DIEGO--(BUSINESS WIRE)--

bioTheranostics, Inc., provider of solutions for metastatic cancer through the development of innovative oncology diagnostic tests, today announced that its PRCISSM Precision Medicine biomarker profiles for non-small cell lung and colorectal cancers have been expanded. The profiles now include 13 non-small cell lung and seven colorectal cancer clinically relevant tumor biomarkers, many of which also may be used in other cancers such as melanoma.

The PRCIS product lineintroduced earlier this yearincludes response, resistance, and tumor biomarkers to drive optimal treatment strategies. The PRCIS tests help oncologists predict potential treatment response and evaluate underlying disease pathways as they consider targeted therapies. These biomarkers are highly actionable and supported by strong clinical evidence.

Richard Ding, CEO of bioTheranostics, said the expanded PRCIS Precision Medicine biomarker profiles reflect the companys commitment to providing the best care for metastatic cancer patientsfrom diagnosis of primary tumor site with the CancerTYPE ID molecular classifier through predictive biomarker testing with PRCIS. Precision medicine requires accurate diagnosis of cancer of origin and precise information about tumor pathways, Ding said. With our industry-leading molecular classifier CancerTYPE ID, and comprehensive and actionable PRCIS tumor biomarkers, bioTheranostics is at the forefront of personalized medicine for metastatic cancers.

The PRCIS profiles include clinically relevant tumor biomarkers EGFR, ALK rearrangement, ALK-mutation for resistance, KRAS, BRAF, NRAS, PIK3CA, 10q23 deletion, c-MET, DDR2, and chemo response biomarkers ERCC1 and RRM1 that aid in characterizing disease pathways and proper molecular targeted therapies. The new profiles are available to clinicians beginning today.

About bioTheranostics

bioTheranostics is the leading solution provider for metastatic cancer management, leveraging its unique expertise in expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID molecular classification test; PRCISSM Precision Medicine, which includes biomarker profiles for non-small cell lung and colorectal cancers; and Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor positive, lymph node negative breast cancer. bioTheranostics, a bioMrieux company, is based in San Diego. For more information, visit http://www.biotheranostics.com.

Read the rest here:
bioTheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic ...